CCO Oncology Podcast

Expert Insight on Important Clinical Trial Data From ESMO 2021 Informing Treatment for Endometrial and Ovarian Cancer

Episode Summary

In this podcast episode, listen to Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, discuss important new clinical trial data for endometrial and ovarian cancers presented at the virtual ESMO 2021 annual meeting.

Episode Notes

In this episode, Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, provide expert insights on key new data from ESMO 2021 presented for endometrial and ovarian cancers including:

• Data from the phase III OReO/ENGOT Ov-38 trial of olaparib rechallenge in patients with recurrent ovarian cancer previously treated with a PARP inhibitor  
• A subgroup analysis of KEYNOTE-775, comparing lenvatinib vs pembrolizumab vs TPC, with outcomes by tumor histology and prior lines of therapy
• A preplanned analysis from phase III NRG-GY004 of outcomes by HRD status for olaparib with or without cediranib vs platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer
• Quality-adjusted time without symptom or toxicity from the phase III PRIMA trial of maintenance niraparib vs placebo in newly diagnosed advanced ovarian cancer

Presenters:

Prof. Isabelle Ray-Coquard, MD, PhD
Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France

Bernard Doger de Spéville, MD, PhD
Medical Oncologist
START-Madrid, Early Phase Clinical Trials Unit
Hospital Fundación Jiménez Díaz
Madrid, Spain

Content supported by an educational grant from GlaxoSmithKline.

Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/3dAttwi